A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic Breast Cancer will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.
Breast Cancer
DRUG: GNC-035
DLT, Dose limiting toxicity, Up to 2 weeks|MTD or MAD, Maximum tolerated dose or maximum administrated dose, Up to 2 weeks|TEAE, Treatment-Emergent Adverse Event, Up to 2 weeks|The recommended dose for future clinical study, The recommended dose for future clinical study, Up to 2 weeks|RP2D, Recommended phase II dose, Up to 2 years
AESI, Adverse Events of special interest, Up to 2 years|Cmax, Maximum serum concentration of GNC-035, Up to 2 weeks|Tmax, Time to maximum serum concentration (Tmax) of GNC-035, Up to 2 weeks|T1/2, Half-life of GNC-035, Up to 2 weeks|Incidence and titer of ADA, Anti-drug antibody, Up to 2 years|ORR, Objective Response Rate, Up to 2 years|DCR, Disease Control Rate, Up to 2 years|PFS, Progression-free Survival, Up to 2 years|DOR, Duration of Response, Up to 2 years
In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in participants with locally advanced or metastatic Breast Cancer will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.